Oorja Bio
Summary active Updated May 23, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Oorja Bio is a Houston, TX-based clinical-stage biopharmaceutical company developing ORJ-001 (a first-in-class therapeutic for idiopathic pulmonary fibrosis (IPF)) and a broader pipeline targeting fibrotic diseases and cardiopulmonary function 123. The company is led by CEO Sujay Kango and CMO Janethe Pena, both former Acceleron Pharma executives (Acceleron was acquired by Merck in 2021 for $11.5B) 23. The $30M Series A announced May 19-20, 2026 was led by Westlake BioPartners (founding investor), with Beth Seidenberg (Founding Managing Director, Westlake BioPartners) leading the investment; the round funded Oorja’s stealth-exit launch with capital to advance ORJ-001 into Phase 2 trials 123.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-05-19 | Series A | $30M | Westlake BioPartners | — 123 |
What Investors Say
“Oorja Bio’s founding team is very well positioned to accelerate promising drug assets and open up a new chapter for treating IPF and other fibrotic diseases — an area of long-standing challenge for drug development that lacks disease modifying therapies. We look forward to continuing to work with the Oorja Bio team as they advance ORJ-001 in the clinic and build a pipeline to bring new therapies that can redefine the standard of care for patients with IPF and fibrotic diseases.”
— Beth Seidenberg, Founding Managing Director, Westlake BioPartners 1
What Founders Say
No independently sourced founder quotes found at this time.
Sources
-
BioSpace, “Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases,” May 19, 2026. Accessed May 2026. https://www.biospace.com/press-releases/oorja-bio-launches-as-a-clinical-stage-company-to-develop-groundbreaking-therapies-for-idiopathic-pulmonary-fibrosis-ipf-and-other-fibrotic-diseases↩↩↩↩
-
BioPharma Dive, “Oorja, run by Acceleron veterans, launches to make new fibrosis drugs,” May 2026. Accessed May 2026. https://www.biopharmadive.com/news/oorja-biotech-startup-westlake-ipf-drug-acceleron/820718/↩↩↩↩
-
FierceBiotech, “With $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate,” May 2026. Accessed May 2026. https://www.fiercebiotech.com/biotech/30m-launch-oorja-bio-breathes-new-life-south-korean-fibrosis-candidate↩↩↩↩